Prosecution Insights
Last updated: May 29, 2026

Grifols Worldwide Operations Limited

9 pending office actions • 7 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
8
Non-Final OAs
0
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
0
Due this month
1
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 60 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
6
Medium (67%)
0
Easy (0%)
3
Unknown (33%)

Rejection Statute Mix

BucketCases
§103 only4 (44%)
Double-patenting + other2 (22%)
No statute on record3 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
89% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
11% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DABKOWSKI, ERINNE R 2 55.8% +69.0%
BOECKELMAN, JACOB A 1 36.1% +46.3%
REYNOLDS, FRED H 1 33.0% +39.2%
DAVIS, RUTH A 1 60.6% +31.1%
PATEL, OM 1 58.3% +53.2%
D' AMBROSIO, THEA 1 55.6% +56.8%
CHEONG, CHEOM-GIL 1 65.0% +54.4%
YAO, LEI 1 60.0% +65.6%

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18248989 UNIT FOR COLLECTING BLOOD AND/OR PLASMA PATEL, OM 114d overdue
18252995 WOUND HEALING DAVIS, RUTH A 87d overdue
18557828 USE OF THERAPEUTIC PLASMA EXCHANGE AND LOW VOLUME PLASMA EXCHANGE FOR THE TREATMENT OF A COGNITIVE IMPAIRMENT BOECKELMAN, JACOB A 49d overdue
18004233 COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS D' AMBROSIO, THEA 25d overdue
18002245 METHOD FOR OBTAINING A COMPOSITION COMPRISING HUMAN PLASMA-DERIVED IMMUNOGLOBULIN M CHEONG, CHEOM-GIL 10d overdue
18543196 USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE DABKOWSKI, ERINNE R 7d
18548545 ALPHA-1 ANTITRYPSIN DOSING REGIMEN REYNOLDS, FRED H 60d
18004231 COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS DABKOWSKI, ERINNE R 75d

Top Art Units

Art UnitApps
1654 3
1655 1
1658 1
1699 1
3791 1
1645 1
1642 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18543196 USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE DABKOWSKI, ERINNE R 1654 Other Non-Final OA 7d Pending Dec 18, 2023
18557828 USE OF THERAPEUTIC PLASMA EXCHANGE AND LOW VOLUME PLASMA EXCHANGE FOR THE TREATMENT OF A COGNITIVE IMPAIRMENT BOECKELMAN, JACOB A 1655 §103 Non-Final OA 49d overdue Pending Oct 27, 2023
18548545 ALPHA-1 ANTITRYPSIN DOSING REGIMEN REYNOLDS, FRED H 1658 DPOther Non-Final OA 60d Pending Aug 31, 2023
18252995 WOUND HEALING DAVIS, RUTH A 1699 §103 Non-Final OA 87d overdue Pending May 15, 2023
18248989 UNIT FOR COLLECTING BLOOD AND/OR PLASMA PATEL, OM 3791 §103 Non-Final OA 114d overdue Pending Apr 13, 2023
18004231 COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS DABKOWSKI, ERINNE R 1654 DPOther Non-Final OA 75d Pending Jan 04, 2023
18004233 COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS D' AMBROSIO, THEA 1654 Other Non-Final OA 25d overdue Pending Jan 04, 2023
18002245 METHOD FOR OBTAINING A COMPOSITION COMPRISING HUMAN PLASMA-DERIVED IMMUNOGLOBULIN M CHEONG, CHEOM-GIL 1645 Other Non-Final OA 10d overdue Pending Dec 16, 2022
18000380 HYPERIMMUNE IGG AND/OR IGM COMPOSITIONS AND METHOD FOR PREPARING THEREOF AND METHOD FOR OBTAINING HYPERIMMUNE HUMAN PLASMA FROM A DONOR YAO, LEI 1642 §103 Non-Final OA 78d Pending Nov 30, 2022

Managing Grifols Worldwide Operations Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month